Lexicon Pharmaceuticals, Inc.SEC Filings
|
|
All SEC filings by Lexicon Pharmaceuticals, Inc. (LXRX) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 6, 2026 | |
| 10-Q | Quarterly report | View Diff | May 7, 2026 | |
| ARS | Annual report to shareholders | Mar 16, 2026 | ||
| 10-K | Annual report | View Diff | Mar 5, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 6, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 6, 2025 | |
| 10-Q | Quarterly report | View Diff | May 14, 2025 | |
| ARS | Annual report to shareholders | Apr 22, 2025 | ||
| 10-K | Annual report | View Diff | Mar 7, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 13, 2024 |
Events
| 8-K | Lexicon Pharmaceuticals Reports Second Quarter 2026 | Aug 6, 2026 | ||
| 8-K | Lexicon Pharmaceuticals Reports First Quarter 2026 | May 7, 2026 | ||
| 8-K | Lexicon Pharmaceuticals Announces $100 Million Loan Facility | May 6, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | Apr 30, 2026 | ||
| 8-K | Lexicon Pharmaceuticals Reports Fourth Quarter 2025 | Mar 5, 2026 | ||
| 8-K | Lexicon Announces Pricing of Approximately $94.6 Million Public | Feb 2, 2026 | ||
| 8-K | Lexicon Announces Proposed Public Offering of Common Stock | Jan 29, 2026 | ||
| 8-K | Other Events | Nov 10, 2025 | ||
| 8-K | Other Events | Nov 6, 2025 | ||
| 8-K | Lexicon Pharmaceuticals Reports Third Quarter 2025 | Nov 6, 2025 |
Registrations and Prospectuses
| S-3 | Shelf registration | View Diff | Aug 6, 2026 | |
| S-8 | Registration of securities for employees | Aug 6, 2026 | ||
| D | $59,150,000 in Equity — 1 Investor | Feb 17, 2026 | ||
| FWP | Free writing prospectus | Feb 6, 2026 | ||
| FWP | Free writing prospectus | Feb 6, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | Feb 2, 2026 | ||
| FWP | Free writing prospectus | Jan 30, 2026 | ||
| FWP | Free writing prospectus | Jan 30, 2026 | ||
| FWP | Free writing prospectus | Jan 29, 2026 | ||
| FWP | Free writing prospectus | Jan 29, 2026 |
Proxies
| DEFA14A | Proxy Filing | Mar 16, 2026 | ||
| DEF 14A | Annual Meeting of Shareholders | View Diff | Mar 16, 2026 | |
| PRE 14A | Annual Meeting of Shareholders | View Diff | Feb 17, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Apr 22, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 22, 2025 | |
| PRE 14A | Preliminary proxy | View Diff | Mar 25, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Mar 26, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Mar 26, 2024 | |
| PRE 14A | Preliminary proxy | View Diff | Mar 11, 2024 | |
| DEFA14A | Additional proxy soliciting materials | Mar 17, 2023 |
Other
| EFFECT | Notice of effectiveness | Aug 17, 2026 | ||
| EFFECT | Notice of effectiveness | Aug 16, 2024 | ||
| CORRESP | Correspondence with SEC | Aug 9, 2024 | ||
| UPLOAD | Letter from SEC | Aug 8, 2024 | ||
| EFFECT | Notice of effectiveness | May 16, 2024 | ||
| CORRESP | Correspondence with SEC | May 13, 2024 | ||
| UPLOAD | Letter from SEC | Mar 29, 2024 | ||
| CT ORDER | Confidential treatment order | Jun 8, 2023 | ||
| EFFECT | Notice of effectiveness | Sep 15, 2021 | ||
| CORRESP | Correspondence with SEC | Sep 10, 2021 |
Ownership
| SC 13G/A | Fmr Llc Updates Stake in Lexicon Pharmaceuticals, Inc. | Aug 6, 2026 | ||
| 4 | Swain Judith L | Jun 4, 2026 | ||
| 4 | Sullivan Diane E. | Jun 4, 2026 | ||
| 4 | Sobecki Christopher J | Jun 4, 2026 | ||
| 4 | Cheung Ivan | Jun 4, 2026 | ||
| 4 | Barker Sam L | Jun 4, 2026 | ||
| 4 | Amouyal Philippe | Jun 4, 2026 | ||
| 4 | Debbane Raymond | Jun 4, 2026 | ||
| 4 | International S.c.a. Artal | May 8, 2026 | ||
| SC 13D/A | Invus Global Management, Llc Updates Stake in Lexicon Pharmaceuticals, Inc. | May 8, 2026 |